Cedars-Sinai Medical Center-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Cedars-Sinai Medical Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011921
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cedars-Sinai Medical Center (Cedars-Sinai), formerly Kaspare Cohn Hospital is an academic and medical center that provides healthcare services for patients and medical professionals, and research and education services. The center offers treatments for various conditions such as abdominal pain, hirschsprung’s disease, nasal polyps, abnormal bleeding, head and neck pain, nosebleeds, pancreatic cancer, and varicocele. Its various programs and services include blood donor services, blood and marrow transplant program, epilepsy program, carcinoid and neuroendocrine tumor program, and nutrition counseling services, among others. Cedars-Sinai also offers continuing education for medical professionals, resources for physicians, and nursing programs. The center offers research in the areas of diabetes and obesity, cancer, digestive diseases, endocrinology, genetics and genomics. Cedars-Sinai is headquartered in Los Angeles, California, the US.

Cedars-Sinai Medical Center – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cedars-Sinai Medical Center, Medical Devices Deals, 2011 to YTD 2017 10
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Naia Rare Diseases to Raise Funds through Series B Financing 13
Emulate Raises USD12 Million in Series A Financing 14
Partnerships 15
XBiotech Enters into Agreement with Cedars-Sinai Medical Center 15
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 16
Treeway Enters into Agreement with Cedars-Sinai Medical Center 17
Cedars-Sinai To Form Joint Venture With UCLA Health System And Select Medical 18
Virginia G. Piper Cancer Center And TGen Enter Into Co-Development Agreement With Samuel Oschin Comprehensive Cancer Institute 19
Licensing Agreements 20
Capricor Therapeutics Amends Licenses Agreement with Cedars-Sinai Medical for Exosomes 20
Naia Enters into Licensing Agreement with Cedars-Sinai Medical Center 22
EOS Biosciences Enters into Licensing Agreement with Cedars-Sinai Medical Center 23
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 24
BioSante Pharma Amends Licensing Agreement with Wake Forest University and Cedars-Sinai 26
Equity Offering 27
Capricor Therapeutics to Raise USD3.7 Million in Private Placement of Shares 27
Capricor Therapeutics Raises USD10 Million in Private Placement of Common Stock 28
Cedars-Sinai Medical Center – Key Competitors 30
Cedars-Sinai Medical Center – Key Employees 31
Cedars-Sinai Medical Center – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Government and Public Interest 34
Feb 01, 2017: New treatment regimen extends life for some men with recurrent prostate cancer, study finds 34
Dec 05, 2016: Cedars-Sinai Receives $10 Million for Pioneering Research on Debilitating Digestive Tract Disease 35
Oct 04, 2016: Revolutionary Clinical Trial Initiative Focuses on Precision Medicine, Collaboration and Data Sharing to Transform Outcomes for All Pancreatic Cancer Patients 36
Sep 12, 2016: Semma Therapeutics Announces $5 Million Grant from California Institute of Regenerative Medicine to Develop Novel Stem-Cell Derived Treatment for Diabetes 38
Jul 19, 2016: ALS research suggests stem cells be ‘aged’ to speed progress toward finding treatments 39
Jun 28, 2016: UCLA Clinical and Translational Science Institute receives $69.6 million grant from NIH 40
Product Approvals 42
Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients 42
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Key Facts 2
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cedars-Sinai Medical Center, Deals By Therapy Area, 2011 to YTD 2017 9
Cedars-Sinai Medical Center, Medical Devices Deals, 2011 to YTD 2017 10
Cedars-Sinai Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Naia Rare Diseases to Raise Funds through Series B Financing 13
Emulate Raises USD12 Million in Series A Financing 14
XBiotech Enters into Agreement with Cedars-Sinai Medical Center 15
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 16
Treeway Enters into Agreement with Cedars-Sinai Medical Center 17
Cedars-Sinai To Form Joint Venture With UCLA Health System And Select Medical 18
Virginia G. Piper Cancer Center And TGen Enter Into Co-Development Agreement With Samuel Oschin Comprehensive Cancer Institute 19
Capricor Therapeutics Amends Licenses Agreement with Cedars-Sinai Medical for Exosomes 20
Naia Enters into Licensing Agreement with Cedars-Sinai Medical Center 22
EOS Biosciences Enters into Licensing Agreement with Cedars-Sinai Medical Center 23
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 24
BioSante Pharma Amends Licensing Agreement with Wake Forest University and Cedars-Sinai 26
Capricor Therapeutics to Raise USD3.7 Million in Private Placement of Shares 27
Capricor Therapeutics Raises USD10 Million in Private Placement of Common Stock 28
Cedars-Sinai Medical Center, Key Competitors 30
Cedars-Sinai Medical Center, Key Employees 31
Cedars-Sinai Medical Center, Other Locations 32
Cedars-Sinai Medical Center, Subsidiaries 33

★海外企業調査レポート[Cedars-Sinai Medical Center-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kering SA:企業のM&A・事業提携・投資動向
    Kering SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kering SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Applied Genetic Technologies Corp (AGTC):企業の財務・戦略的SWOT分析
    Summary Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. It offers products such as x-linked retinoschisis, achromatopsia, x-linked retinitis pi …
  • National Company KazMunayGas-石油・ガス分野:企業M&A・提携分析
    Summary National Company KazMunayGas (KazMunayGas) is a state-owned, vertically integrated oil and gas company. It carries out the acquisition, exploration, development, production, processing, transportation, refining and export of hydrocarbons. The company also produces petrochemicals, stores and …
  • Lee’s Pharmaceutical Holdings Ltd (950):製薬・医療:M&Aディール及び事業提携情報
    Summary Lee's Pharmaceutical Holdings Ltd (Lee's Pharmaceutical) is a biopharmaceutical company that offers development of novel therapies and contract research services. The company provides products in the treatment of disease areas such as urology, cardiovascular oncology, dermatology, hematology …
  • Qatar Fuel (WOQOD) Q.S.C. (QFLS):企業の財務・戦略的SWOT分析
    Qatar Fuel (WOQOD) Q.S.C. (QFLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Qvella Corp:医療機器:M&Aディール及び事業提携情報
    Summary Qvella Corp (Qvella) is a molecular diagnostics company which develops differentiated technology for rapid detection of pathogens causing Sepsis by direct sampling of bodily fluids. Its Field Activated Sample Treatment (FAST) -ID technology utilizes a novel electrical lysing and sample treat …
  • McConnell Dowell Corp Ltd:企業の戦略的SWOT分析
    McConnell Dowell Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Valeant Pharmaceuticals International Inc (VRX)-医療機器分野:企業M&A・提携分析
    Summary Valeant Pharmaceuticals International Inc (Valeant) is a pharmaceutical and medical device company that carries out development, manufacture and marketing of several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, int …
  • Bio-Modeling Systems SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Bio-Modeling Systems SAS (BM Systems) is a biotechnology company that discovers and develops novel diagnostic, therapeutic and prevention solutions. The company owns an operational mechanisms-based medicine platform known as computer-assisted deductive integration (CADI), which is used in th …
  • Long Chen Paper Co., Ltd.:企業の戦略・SWOT・財務情報
    Long Chen Paper Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Long Chen Paper Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • United Therapeutics Corp (UTHR)-医療機器分野:企業M&A・提携分析
    Summary United Therapeutics Corp (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (tre …
  • Corvidia Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Corvidia Therapeutics Inc (Corvidia Therapeutics) is a clinical stage biotechnology company that develops cardiovascular and cardio-renal therapies leveraging functional genomics. The company develops COR-001 for the treatment of chronic kidney disease on dialysis (under phase 2 stage), and …
  • Visiomed Group SA (ALVMG):医療機器:M&Aディール及び事業提携情報
    Summary Visiomed Group SA (Visiomed) is a medical device company. The company develops and distributes electronic medical devices. It offers screening and diagnosis products, pain relief products, prevention and treatment products, hearing and optics, family hygiene, children’s optics, baby bottle t …
  • California Pizza Kitchen, Inc.:企業の戦略・SWOT・財務分析
    California Pizza Kitchen, Inc. - Strategy, SWOT and Corporate Finance Report Summary California Pizza Kitchen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Leukocare AG-医療機器分野:企業M&A・提携分析
    Summary Leukocare AG (Leukocare) is a clinical stage biotechnology company that offers technologies for stabilizing proteins to increase shelf-life and to facilitate terminal sterilization by irradiation or gas. The company offers services such as development of individual SPS formulations meeting i …
  • Molecular Templates Inc:企業のM&A・事業提携・投資動向
    Molecular Templates Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Molecular Templates Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Abu Dhabi Commercial Bank (ADCB):企業の財務・戦略的SWOT分析
    Summary Abu Dhabi Commercial Bank (ADCB) offers traditional and Islamic banking solutions to individuals, high net worth individuals, government, and corporate customers. Its product and service portfolio comprises current and savings accounts; fixed deposits; debit and credit cards; savings and pro …
  • GarrettCom, Inc.:企業の戦略的SWOT分析
    GarrettCom, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Costco Wholesale UK Limited:企業の戦略・SWOT・財務分析
    Costco Wholesale UK Limited - Strategy, SWOT and Corporate Finance Report Summary Costco Wholesale UK Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Nichi-Iko Pharmaceutical Co Ltd (4541):企業の財務・戦略的SWOT分析
    Summary Nichi-Iko Pharmaceutical Co Ltd (Nichi-Iko) is a manufacturer of generic products. The company eripheral nervous system medicines. The company offers products such as alacepril tablets, aluminum hydroxide gel, aranidipine capsules, bacampicillin hydrochloride tablets, barium sulfate, betahis …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆